Literature DB >> 27111280

Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.

Takuro Saito1,2, Hiroyoshi Nishikawa1, Hisashi Wada2,3, Yuji Nagano4, Daisuke Sugiyama1, Koji Atarashi4, Yuka Maeda1, Masahide Hamaguchi1, Naganari Ohkura1, Eiichi Sato5, Hirotsugu Nagase2, Junichi Nishimura2, Hirofumi Yamamoto2, Shuji Takiguchi2, Takeshi Tanoue4, Wataru Suda6, Hidetoshi Morita7, Masahira Hattori6, Kenya Honda4, Masaki Mori2, Yuichiro Doki2, Shimon Sakaguchi1.   

Abstract

CD4(+) T cells that express the forkhead box P3 (FOXP3) transcription factor function as regulatory T (Treg) cells and hinder effective immune responses against cancer cells. Abundant Treg cell infiltration into tumors is associated with poor clinical outcomes in various types of cancers. However, the role of Treg cells is controversial in colorectal cancers (CRCs), in which FOXP3(+) T cell infiltration indicated better prognosis in some studies. Here we show that CRCs, which are commonly infiltrated by suppression-competent FOXP3(hi) Treg cells, can be classified into two types by the degree of additional infiltration of FOXP3(lo) nonsuppressive T cells. The latter, which are distinguished from FOXP3(+) Treg cells by non-expression of the naive T cell marker CD45RA and instability of FOXP3, secreted inflammatory cytokines. Indeed, CRCs with abundant infiltration of FOXP3(lo) T cells showed significantly better prognosis than those with predominantly FOXP3(hi) Treg cell infiltration. Development of such inflammatory FOXP3(lo) non-Treg cells may depend on secretion of interleukin (IL)-12 and transforming growth factor (TGF)-β by tissues and their presence was correlated with tumor invasion by intestinal bacteria, especially Fusobacterium nucleatum. Thus, functionally distinct subpopulations of tumor-infiltrating FOXP3(+) T cells contribute in opposing ways to determining CRC prognosis. Depletion of FOXP3(hi) Treg cells from tumor tissues, which would augment antitumor immunity, could thus be used as an effective treatment strategy for CRCs and other cancers, whereas strategies that locally increase the population of FOXP3(lo) non-Treg cells could be used to suppress or prevent tumor formation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27111280     DOI: 10.1038/nm.4086

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  34 in total

1.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.

Authors:  Kosuke Mima; Reiko Nishihara; Zhi Rong Qian; Yin Cao; Yasutaka Sukawa; Jonathan A Nowak; Juhong Yang; Ruoxu Dou; Yohei Masugi; Mingyang Song; Aleksandar D Kostic; Marios Giannakis; Susan Bullman; Danny A Milner; Hideo Baba; Edward L Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Wendy S Garrett; Curtis Huttenhower; Matthew Meyerson; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino
Journal:  Gut       Date:  2015-08-26       Impact factor: 23.059

Review 2.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

3.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development.

Authors:  Naganari Ohkura; Masahide Hamaguchi; Hiromasa Morikawa; Kyoko Sugimura; Atsushi Tanaka; Yoshinaga Ito; Motonao Osaki; Yoshiaki Tanaka; Riu Yamashita; Naoko Nakano; Jochen Huehn; Hans Joerg Fehling; Tim Sparwasser; Kenta Nakai; Shimon Sakaguchi
Journal:  Immunity       Date:  2012-11-01       Impact factor: 31.745

Review 4.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

5.  Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment.

Authors:  Aleksandar D Kostic; Eunyoung Chun; Lauren Robertson; Jonathan N Glickman; Carey Ann Gallini; Monia Michaud; Thomas E Clancy; Daniel C Chung; Paul Lochhead; Georgina L Hold; Emad M El-Omar; Dean Brenner; Charles S Fuchs; Matthew Meyerson; Wendy S Garrett
Journal:  Cell Host Microbe       Date:  2013-08-14       Impact factor: 21.023

6.  Microbiota organization is a distinct feature of proximal colorectal cancers.

Authors:  Christine M Dejea; Elizabeth C Wick; Elizabeth M Hechenbleikner; James R White; Jessica L Mark Welch; Blair J Rossetti; Scott N Peterson; Erik C Snesrud; Gary G Borisy; Mark Lazarev; Ellen Stein; Jamuna Vadivelu; April C Roslani; Ausuma A Malik; Jane W Wanyiri; Khean L Goh; Iyadorai Thevambiga; Kai Fu; Fengyi Wan; Nicolas Llosa; Franck Housseau; Katharine Romans; XinQun Wu; Florencia M McAllister; Shaoguang Wu; Bert Vogelstein; Kenneth W Kinzler; Drew M Pardoll; Cynthia L Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

7.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

8.  Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer.

Authors:  Nichole R Blatner; Mary F Mulcahy; Kristen L Dennis; Denise Scholtens; David J Bentrem; Joseph D Phillips; Soo Ham; Barry P Sandall; Mohammad W Khan; David M Mahvi; Amy L Halverson; Steven J Stryker; Anne-Marie Boller; Ashima Singal; Rebekka K Sneed; Bara Sarraj; Mohammed Javeed Ansari; Martin Oft; Yoichiro Iwakura; Liang Zhou; Andreas Bonertz; Philipp Beckhove; Fotini Gounari; Khashayarsha Khazaie
Journal:  Sci Transl Med       Date:  2012-12-12       Impact factor: 17.956

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing.

Authors:  Seok-Won Kim; Wataru Suda; Sangwan Kim; Kenshiro Oshima; Shinji Fukuda; Hiroshi Ohno; Hidetoshi Morita; Masahira Hattori
Journal:  DNA Res       Date:  2013-04-09       Impact factor: 4.458

View more
  276 in total

1.  Tumor SQSTM1 (p62) expression and T cells in colorectal cancer.

Authors:  Keisuke Kosumi; Yohei Masugi; Juhong Yang; Zhi Rong Qian; Sun A Kim; Wanwan Li; Yan Shi; Annacarolina da Silva; Tsuyoshi Hamada; Li Liu; Mancang Gu; Tyler S Twombly; Yin Cao; David A Barbie; Katsuhiko Nosho; Hideo Baba; Wendy S Garrett; Jeffery A Meyerhardt; Edward L Giovannucci; Andrew T Chan; Charles S Fuchs; Shuji Ogino; Reiko Nishihara
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

2.  Histidine decarboxylase (HDC)-expressing granulocytic myeloid cells induce and recruit Foxp3+ regulatory T cells in murine colon cancer.

Authors:  Xiaowei Chen; Yoshihiro Takemoto; Huan Deng; Moritz Middelhoff; Richard A Friedman; Timothy H Chu; Michael J Churchill; Yan Ma; Karan K Nagar; Yagnesh H Tailor; Siddhartha Mukherjee; Timothy C Wang
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

Review 3.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

4.  Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.

Authors:  Tomasz Maj; Wei Wang; Joel Crespo; Hongjuan Zhang; Weimin Wang; Shuang Wei; Lili Zhao; Linda Vatan; Irene Shao; Wojciech Szeliga; Costas Lyssiotis; J Rebecca Liu; Ilona Kryczek; Weiping Zou
Journal:  Nat Immunol       Date:  2017-10-30       Impact factor: 25.606

Review 5.  Roles of regulatory T cells in cancer immunity.

Authors:  Yoshiko Takeuchi; Hiroyoshi Nishikawa
Journal:  Int Immunol       Date:  2016-05-09       Impact factor: 4.823

6.  Score of the preoperative absolute number of lymphocytes, monocytes, and neutrophils as a prognostic indicator for patients with gastric cancer.

Authors:  Hiroaki Saito; Shota Shimizu; Yusuke Kono; Yuki Murakami; Yuji Shishido; Kozo Miyatani; Tomoyuki Matsunaga; Yoji Fukumoto; Keigo Ashida; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2019-05-06       Impact factor: 2.549

7.  HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Authors:  Bianca Cioni; Ekaterina S Jordanova; Erik Hooijberg; Rianne van der Linden; Renee X de Menezes; Katherine Tan; Stefan Willems; Joris B W Elbers; Annegien Broeks; Andries M Bergman; Charlotte L Zuur; Jan Paul de Boer
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

8.  IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors.

Authors:  Gavin Whitehouse; Elizabeth Gray; Sotiris Mastoridis; Elliot Merritt; Elisavet Kodela; Jennie H M Yang; Richard Danger; Marta Mairal; Sofia Christakoudi; Juan J Lozano; Iain C Macdougall; Timothy I M Tree; Alberto Sanchez-Fueyo; Marc Martinez-Llordella
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

9.  Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells.

Authors:  Y You; Y Li; M Li; M Lei; M Wu; Y Qu; Y Yuan; T Chen; H Jiang
Journal:  Clin Exp Immunol       Date:  2017-10-23       Impact factor: 4.330

10.  Tumour-associated changes in intestinal epithelial cells cause local accumulation of KLRG1+ GATA3+ regulatory T cells in mice.

Authors:  Holger Meinicke; Anna Bremser; Maria Brack; Paulina Akeus; Claire Pearson; Samuel Bullers; Katrin Hoffmeyer; Marc P Stemmler; Marianne Quiding-Järbrink; Ana Izcue
Journal:  Immunology       Date:  2017-06-19       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.